87 Results for "

SHR

" in MedChemExpress (MCE) Product Catalog:
Products (87)

87 Results for "SHR" in MCE Product Catalog:

18
18 Publications Verification
Cat. No.: HY-104065
CAS No.: 1269662-73-8
Purity:  99.89%
Synonyms: SHR-1258
Target:  

EGFR

Research Areas:  

Cancer

Pyrotinib (SHR-1258) is a potent and selective EGFR/HER2 dual inhibitor with IC50s of 13 and 38 nM, respectively .
loading...
    loading...
18
18 Publications Verification
Cat. No.: HY-104065B
CAS No.: 1397922-61-0
Purity:  98.01%
Synonyms: SHR-1258 dimaleate
Target:  

EGFR

Research Areas:  

Cancer

Pyrotinib dimaleate (SHR-1258 dimaleate) is a potent and selective EGFR/HER2 dual inhibitor with IC50s of 13 and 38 nM, respectively .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-114778
CAS No.: 1358715-18-0
Purity:  99.96%
Synonyms: SHR3162; Fuzuloparib
Target:  

PARP

Research Areas:  

Cancer

Fluzoparib (SHR3162) is a potent and orally active PARP1 inhibitor (IC50=1.46±0.72 nM, a cell-free enzymatic assay) with superior antitumor activity. Fluzoparib selectively inhibits the proliferation of homologous recombination repair (HR)-deficient cells, and sensitizes both HR-deficient and HR-proficient cells to cytotoxic agents. Fluzoparib exhibits good pharmacokinetic properties in vivo and can be used for BRCA1/2-mutant relapsed ovarian cancer research .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-P9971
CAS No.: 1798286-48-2
Synonyms: SHR-1210; INCSHR1210

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-114338
CAS No.: 1637781-04-4
Purity:  99.70%
Synonyms: SHR-6390
Target:  

CDK

Research Areas:  

Cancer

Dalpiciclib (SHR-6390) is an orally active and highly selective inhibitor of CDK4 and 6 with IC50 values of 12.4 nM and 9.9 nM, respectively . Dalpiciclib shows antitumor activity against breast cancer and esophageal squamous cell carcinoma .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-114338A
CAS No.: 2891598-76-6
Purity:  98.22%
Synonyms: SHR-6390 hydrochloride
Target:  

CDK

Research Areas:  

Cancer

Dalpiciclib (SHR-6390) hydrochloride is an orally active and highly selective inhibitor of CDK4 and 6 with IC50 values of 12.4 nM and 9.9 nM, respectively . Dalpiciclib hydrochloride shows antitumor activity against breast cancer and esophageal squamous cell carcinoma .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-14744
CAS No.: 103129-82-4
Purity:  98.53%
Synonyms: (S)-Amlodipine; Levoamlodipine
Levamlodipine ((S)-Amlodipine; Levoamlodipin) is an orally active L-type calcium channel blocker and MMP-9 modulator with high permeability and retention properties. Levamlodipine significantly enhances plaque stability and improves lipid profiles by reducing blood pressure, decreasing systolic blood pressure variability, and inhibiting MMP-9 expression in atherosclerotic plaques. Levamlodipine not only alleviates cardiac and aortic hypertrophy and prevents renal atrophy, but also produces synergistic effects in blood pressure reduction and organ protection when combined with bisoprolol (HY-129029). Levamlodipine exerts no significant inhibitory effect on abdominal aortic intimal hyperplasia. When excessively accumulated in the epidermis, Levamlodipine may induce changes in keratin structure, impair the skin barrier and trigger inflammation; long-term use further exacerbates skin irritation caused by local administration. Levamlodipine can be used in research related to hypertension and atherosclerosis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-B0612A
CAS No.: 132866-11-6
Lercanidipine is a third-generation, lipophilic, brain-penetrant, vascular-selective and orally active dihydropyridine-calcium channel blocker with a pIC50 of 7.74 (converts from μM). Lercanidipine has long lasting antihypertensive action as well as reno- and neuro-protective effect. Lercanidipine also shows anti-oxidant, anti-inflammatory and anti-apoptotic properties. Lercanidipine can be used in cardiovascular and neurological research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-B0612
CAS No.: 100427-26-7
Lercanidipine is a third-generation, lipophilic, brain-penetrant, vascular-selective and orally active dihydropyridine-calcium channel blocker with a pIC50 of 7.74 (converts from μM). Lercanidipine has long lasting antihypertensive action as well as reno- and neuro-protective effect. Lercanidipine also shows anti-oxidant, anti-inflammatory and anti-apoptotic properties. Lercanidipine can be used in cardiovascular and neurological research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N6924
CAS No.: 80930-74-1
Zingibroside R1 is an orally active triterpene saponin with multiple biological activities including antioxidant, anti-inflammatory, antiviral, and metabolic regulatory properties. Zingibroside R1 reduces the expression of PIN family members, inhibits the expression of PLT1/PLT2, WOX5, SHR, and SCR, disrupts auxin transport and distribution, triggers plant ROS responses, and inhibits root growth. Zingibroside R1 extends the lifespan of Caenorhabditis elegans, enhances its heat stress resistance, and improves its motor ability. Hydrogel derivatives of Zingibroside R1 inhibit the proliferation of Candida albicans by binding to its β-1,3-glucan and exhibit antifungal activity. Zingibroside R1 inhibits GLUT1-mediated uptake and alleviates liver injury. Zingibroside R1 can be used in research related to neurodegenerative diseases, vulvovaginal candidiasis, acute liver injury, Ehrlich ascites tumor and HIV-1 infection .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-128351
CAS No.: 2231770-73-1
Purity:  99.69%
Target:  

Oxytocin Receptor

Research Areas:  

Neurological Disease Endocrinology

SHR1653 is a highly potent, selective and brain penetrated oxytocin receptor (OTR) antagonist, with an IC50 of 15 nM for hOTR .
loading...
    loading...
Cat. No.: HY-148668
CAS No.: 2414254-51-4
Purity:  97.37%
Synonyms: SHR-A1811 Drug-linker
Research Areas:  

Cancer

MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan (SHR-A1811 Drug-linker) is a agent-linker conjugates for ADC, consisting Exatecan (HY-13631). Exatecan is a DNA Topoisomerase I inhibitor (IC50=2.2 μM) .
loading...
    loading...
Cat. No.: HY-123011
CAS No.: 1623804-44-3
Synonyms: SHR3824
Target:  

SGLT

Research Areas:  

Metabolic Disease

Henagliflozin (SHR3824) is a potent selective sodium-glucose co-transporter 2 (SGLT2) inhibitor with the IC50 values of 2.38 and 4324 nM for human SGLT2 and SGLT1, respectively. Henagliflozin can be used in diabetes research .
loading...
    loading...
Cat. No.: HY-108713
CAS No.: 1044040-56-3
Purity:  98.13%
Synonyms: SHR1020
Target:  

VEGFR PDGFR Apoptosis

Research Areas:  

Cancer

Famitinib (SHR1020), an orally active multi-targeted kinase inhibitor, inhibits the activity of c-kit, VEGFR-2 and PDGFRβ with IC50 values of 2.3 nM, 4.7 nM and 6.6 nM, respectively . Famitinib exerts powerful antitumor activity in human gastric cancer cells and xenografts. Famitinib triggers apoptosis .
loading...
    loading...
Cat. No.: HY-112724
CAS No.: 1445987-21-2
Purity:  99.82%
Synonyms: SHR0302
Target:  

JAK Apoptosis

Research Areas:  

Inflammation/Immunology Cancer

Ivarmacitinib (SHR0302) is a potent and orally active all members of the JAK family inhibitor, particularly JAK1. The selectivity of Ivarmacitinib for JAK1 is >10-fold for JAK2, 77-fold for JAK3, 420-fold for Tyk2. Ivarmacitinib inhibits JAK1-STAT3 phosphorylation and induces the apoptosis of hepatic stellate cells. Ivarmacitinib has anti-proliferative and anti-inflammatory effects .
loading...
    loading...
Cat. No.: HY-156617A
CAS No.: 2414254-37-6
Purity:  99.75%
Synonyms: SHR169265
Research Areas:  

Cancer

(αR)-Cyclopropaneacetamide-Exatecan (SHR169265) is a DNA Topoisomerase I inhibitor with enhanced membrane permeability (with an IC50 of 1.34 μM against the human DNA Topoisomerase I). (αR)-Cyclopropaneacetamide-Exatecan exerts cytotoxic effects by inhibiting the enzymatic activity of Topoisomerase I, and this anticancer effect is independent of the expression level of HER2. (αR)-Cyclopropaneacetamide-Exatecan is an ADC Cytotoxin derived from Exatecan (HY-13631), which can be used in research related to advanced cancers such as breast cancer, gastric cancer, colorectal cancer and non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-P99944
CAS No.: 2891860-17-4
Synonyms: Retlirafusp alfa

Research Areas:  

Cancer

SHR-1701 (Retlirafusp alfa) is a bifunctional fusion protein targeting PD-L1 and TGF-β for cancer research .
loading...
    loading...
Cat. No.: HY-P99422
CAS No.: 2247114-85-6
Synonyms: SHR-1316

Target:  

PD-1/PD-L1 Apoptosis

Research Areas:  

Cancer

Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC) .
loading...
    loading...
Cat. No.: HY-W005255
CAS No.: 621-54-5
3-(3-Hydroxyphenyl)propionic acid (3HPPA) is an endothelium-dependent nitric oxide (NO) release promoter and endothelial nitric oxide synthase (eNOS) activator. 3-(3-Hydroxyphenyl)propionic acid activates eNOS to mediate vascular smooth muscle relaxation and enhances endothelial cell NO synthesis, inducing vasodilation and reducing peripheral vascular resistance. 3-(3-Hydroxyphenyl)propionic acid can dose-dependently reduce systolic and diastolic blood pressure in spontaneously hypertensive rats (SHR) without affecting cardiac contractility or heart rate. 3-(3-Hydroxyphenyl)propionic acid has antihypertensive and vascular protective effects and can be used in the prevention and treatment of cardiovascular diseases .
loading...
    loading...
Cat. No.: HY-164762
CAS No.: 2924909-11-3
Synonyms: SHR-A1811
Trastuzumab rezetecan (SHR-A1811) is a HER2-targeting antibody-drug conjugate (ADC). Trastuzumab rezetecan is composed of a humanized anti-HER2 antibody (HY-P9907), a cleavable linker MC-Gly-Gly-Phe-Gly (HY-44246), and a topoisomerase I inhibitor payload Rezetecán (HY-147408). Trastuzumab rezetecan can be used for research in HER2-positive breast cancer .
loading...
    loading...